EBV-Associated Lymphoma Consortium Annual Meeting (Abstract)

Abstract Submission

Submission information

Submission Number: 5

Submission ID: 150772

Submission UUID: a3c7d132-125a-4b6c-95a6-80d03a9430f9

Submission URI: /nci/ealv/venue/abstract

Submission Update: /nci/ealv/venue/abstract?token=PprXLdm5f8_0EEIVoIKYgYMyj_yeoxEux3P0vGrfhn0

Created: Wed, 09/03/2025 - 13:28

Completed: Wed, 09/03/2025 - 13:28

Changed: Wed, 09/03/2025 - 13:28

Remote IP address: 10.208.24.230

Submitted by: Anonymous

Language: English

Is draft: No

Webform: EBV-Associated Lymphoma Consortium Annual Meeting (Abstracts)

Submitted to: EBV-Associated Lymphoma Consortium Annual Meeting (Abstract)

OMB No.: 0925-0740
Expiration Date: 9/30/2025

Public reporting burden for this collection of information is estimated to average 60 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0740). Do not return the completed form to this address.

Presenter Information

Please enter information for the person who will be the primary presenter/speaker/author.

First Name

Middle Initial

Last Name

Degree(s)

Please use the following formatting for these degrees: M.D. Ph.D. MPH

Position/Title/Career Status

Organization

Organization City/Town

Please provide a contact email for conference organizers to reach you.

Abstract Information

Abstract Keywords

Up to five keywords of your choice

Abstract Title

Abstract Summary

EBV is associated with the development of Post-Transplant Lymphoproliferative Disease (PTLD) in immunosuppressed solid organ and hematopoietic stem cell recipients. Prior studies from our group identified mutations (G212S and S366T) in latent member protein 1 (LMP1) of EBV that were associated with EBV+ PTLD (OR=11.7). However, some matched controls also carried both LMP1 mutations and did not develop EBV+ PTLD. Therefore, we analyzed LMP1 in EBV+ PTLD cases with the G212S and S366T mutations (n=28), EBV-seropositive transplant controls without PTLD that also have the two LMP1 mutations (n=48), and EBV-seropositive transplant controls without the LMP1 mutations (n=11) to determine if other non-synonymous changes were associated with EBV+ PTLD.  We identified three highly mutated sites in EBV+ PTLD LMP1 (S309N, Q334R, and L338S or L338P), however these amino acid changes were also seen at similar frequencies in LMP1 from controls. Patients with EBV+ PTLD had fewer non-synonymous changes (mean 7.57, SE 0.551) in LMP1 compared to controls (mean 9.08, SE 0.506), and there were no novel non-synonymous changes in LMP1 associated with EBV+ PTLD. We also compared the frequency of the well-described 10 amino acid deletion in LMP1 and while the deletion was more common in LMP1 from EBV+ PTLD cases, there was no significant difference in the deletion frequency in cases and controls. Finally, we analyzed the HLA-E*01:03 epitope (GGDPHLPTL) previously characterized by our group to strongly bind and stabilize HLA-E. We did not observe any significant enrichment of nonsynonymous mutations in the LMP1 sequence encoding this motif in cases or controls.  Our data demonstrates that considerable genetic variability exists in the c-terminal domain of LMP1. However, no specific variation appears to predict the development of EBV+ PTLD. It is possible that predictive and/or functional genetic variants may occur in other EBV genes which is the focus of on-going studies.